George 2003.

Methods	SELEGILINE Randomized controlled trial Setting: outpatient smoking research clinic, USA Recruitment: community volunteers
Participants	40 smokers, CO ≥10 ppm; 63% F, av. age 49, av. CPD 23, 25% MDD history positive
Interventions	1. Selegiline 10 mg/day for 9 weeks (5 mg/day in w1 & w9) 2. Placebo
Outcomes	Abstinence at 6m (7 day PP) Validation: CO < 10ppm
Notes	"The main side effects of SEL were anorexia, gastrointestinal symptoms, and insomnia. None of the differences in adverse event ratings were significant in the SEL compared with the PLA group, and the drug was well tolerated compared with the placebo group. Reports of anxiety/agitation in both the SEL and PLA groups during the trial were high." Funding: National Institute on Drug Abuse, U.S. Department of Veteran Affairs, National Alliance for Research on Schizophrenia and Depression
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomization method not described.
Allocation concealment (selection bias)	Unclear risk	Method not described.
Blinding (performance bias and detection bias) All outcomes	Low risk	Double‐blind, adequacy of blinding tested in research staff; results suggested blinding was adequate.
Incomplete outcome data (attrition bias) All outcomes	High risk	29/40 not assessed at 6m. Greater loss to follow‐up in placebo, exact data not reported.